In this episode, we delve into the history of frontline treatment in young/fit patients with Hodgkin's lymphoma and recent developments in the past decade with Dr. Nancy Bartlett from Washington University.Link for our Blood Cancer Talks Survey: https://bit.ly/BCTSHere are the key trials we discussed:1. RATHL Trial (PET-adapted treatment of Advanced Hodgkin’s Lymphoma):https://pubmed.ncbi.nlm.nih.gov/27332902/ 2. S0816 (PET-adapted treatment of Advanced Hodgkin’s Lymphoma):https://pubmed.ncbi.nlm.nih.gov/27069074/ 3. ECHELON-1 (Replacing Bleomycin by Brentuximab Vedotin in Advanced Hodgkin’s Lymphoma):https://pubmed.ncbi.nlm.nih.gov/29224502/https://pubmed.ncbi.nlm.nih.gov/35830649/ 4. BREACH (BV-AVD vs ABVD for Early Stage Unfavorable Hodgkin’s Lymphoma):https://pubmed.ncbi.nlm.nih.gov/35867960/ 5. S1826 (Nivo-AVD vs BV-AVD in Advanced Hodgkin’s Lymphoma):https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.17_suppl.LBA4 6. FIL-ROUGE (PET-adapted ABVD vs Dose-Intensified ABVD):https://onlinelibrary.wiley.com/doi/10.1002/hon.3163_4 7. HD21 (BRECADD vs EBEACOPP in Advanced Hodgkin’s Lymphoma):https://onlinelibrary.wiley.com/doi/10.1002/hon.3196_LBA5

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related